The IMpower110 phase 3 randomized trial reported similar results in patients with advanced NSCLC and PDL1 expression on ≥1% of tumor cells or tumor-infiltrating lymphocytes who received first-line atezolizumab monotherapy (48). This evidence concerns the gene CD274 and non-small cell lung carcinoma.